Key Highlights

  • Corbus Pharmaceuticals announced favorable Phase 1b CANYON-1 trial results for once-daily oral CRB-913 in obesity.
  • The trial showed statistically significant weight reduction across all cohort dosages.
  • The 60 mg arm showed a 5.0% average decrease at 12 weeks with no observed plateau.
  • The safety profile was tolerable, with no suicidal Ideation signals observed.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) announced favorable Phase 1b CANYON-1 trial results evaluating once-daily oral CRB-913 for obesity, demonstrating statistically significant weight reduction across all cohort dosages.

What Happened

The results were highlighted by a 5.0% average decrease in the 60 mg arm at 12 weeks with no observed plateau, alongside a tolerable safety profile devoid of suicidal ideation signals, paving the way for regulatory interactions and a Phase 2 monotherapy trial commencement targeted for the first half of 2027.

Market Reaction

The disclosed information does not include stock price or trading data for Corbus Pharmaceuticals following the CANYON-1 results.

Outlook

Planned regulatory interactions and the targeted Phase 2 monotherapy trial start in the first half of 2027 represent the next major disclosed milestones for CRB-913 in obesity.